Abstract
Purpose
To review options for ovarian stimulation before oocyte collection for fertility preservation for women with cancer or related diseases who require potentially sterilizing chemo- or radiotherapy.
Methods
Narrative review of current practice.
Results
Vitrification of oocytes and embryos has improved chances of pregnancy for this group of patients in recent years, increasing the uptake of fertility preservation before cancer treatment substantially. Strategies for ovarian stimulation for such patients should optimize oocyte yield whilst avoiding risk of ovarian hyperstimulation.
Conclusions
Best practice in ovarian stimulation can deliver good numbers of oocytes or embryos for cryopreservation with minimal risk of ovarian hyperstimulation for women under 36 years of age. Results are less encouraging for older patients.
Similar content being viewed by others
References
Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update. 2004;10:251–66.
Song WY, Sun YP, Jin HX, Xin ZM, Su YC, Chian RC. Clinical outcome of emergency egg vitrification for women when sperm extraction from the testicular tissues of the male partner is not successful. Syst Biol Reprod Med. 2011;57:210–3. doi:10.3109/19396368.2011.566666.
Cobo A, Meseguer M, Remohí J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25:2239–46. doi:10.1093/humrep/deq146.
Kim TJ, Laufer LR, Hong SW. Vitrification of oocytes produces high pregnancy rates when carried out in fertile women. Fertil Steril. 2010;93:467–74. doi:10.1016/j.fertnstert.2008.12.094.
Nagy ZP, Chang CC, Shapiro DB, Bernal DP, Kort HI, Vajta G. The efficacy and safety of human oocyte vitrification. Semin Reprod Med. 2009;27:450–5. doi:10.1055/s-0029-1241054.
Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentre study. Hum Reprod. 2012;27:1606–12.
Vajta G, Nagy ZP, Cobo A, Conceicao J, Yovich J. Vitrification in assisted reproduction: myths, mistakes, disbeliefs and confusion. Reprod Biomed Online. 2009;19(Suppl3):1–7.
Youssef MAFM, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011, Issue 1. Art. No.: CD008046. doi:10.1002/14651858.CD008046.
Stowitzki T. Ovarian stimulation in cancer patients. European Society of Human Reproduction and Embryology Campus Workshop: Cancer and Fertility. Heidelberg Nov14–15th 2008.
Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Gen. 2012;29:503–5.
Friedman BE, Pao S, Westphal LM, Lathi RB. Oocyte retrieveal following continued stimulation five days beyond ovulations yields live birth after frozen embryo transfer. J Assist Reprod Gen. 2012;29:433–5.
Kim SS, Donnez J, Barri P, et al. Recommendations for fertility preservation in patients with lymphoma, leukaemia and breast cancer. ISFP Practice Committee. J Assist Reprod Gen. 2012;29:465–8.
Checa Vizcaino MA, Chorchado AR, Cuadari ME, et al. The effects of letrazole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online. 2012;24:606–10.
Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrazole and gonadotropins in patients with breast cancer. J ClinOncol. 2008;26:2630–5.
Henes M, Henes JC, Neunhoeffer E, et al. Fertility preservation methods in young women with SLE prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus. 2012;21:953–8.
Peddie VL, Porter MA, Barbour R, et al. Factors affecting decision making about fertility preservation after cancer diagnosis: a qualitative study. BJObsGyn. 2012;119:1049–57.
Author information
Authors and Affiliations
Corresponding author
Additional information
Capsule
Specific patient groups have higher risk of complications of superovulation, including possibility of stimulation of tumor growth for women with ER+ breast cancers and pelvic haematoma for thrombocytopaenic patients with haematological disorders.
Guest Editors: Ri-Cheng Chian & Jia-Yin Liu; Editor-in-Chief: David F. Albertini
Rights and permissions
About this article
Cite this article
Koch, J., Ledger, W. Ovarian stimulation protocols for onco-fertilty patients. J Assist Reprod Genet 30, 203–206 (2013). https://doi.org/10.1007/s10815-013-9947-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-013-9947-7